<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417804</url>
  </required_header>
  <id_info>
    <org_study_id>2017.156(133-DEFI/125-CES)</org_study_id>
    <nct_id>NCT03417804</nct_id>
  </id_info>
  <brief_title>Incidence of Postoperative Residual Neuromuscular Blockade in Portugal</brief_title>
  <official_title>Incidence of Postoperative Residual Neuromuscular Blockade - A Multicenter, Observational Study in Portugal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar do Porto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an epidemiological multicenter, observational, prospective study, designed to&#xD;
      determine the incidence of postoperative residual neuromuscular blockade - defined by a TOF&#xD;
      (train-of-four) ratio &lt; 0.9 - at PACU arrival.&#xD;
&#xD;
      Subjects aged at least 18 years old (n=360) admitted for different types of elective surgical&#xD;
      procedures requiring general anesthesia with neuromuscular blocking agents will be included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, observational/non-interventional study involving adult patients&#xD;
      undergoing different types of elective surgical procedures requiring general anesthesia with&#xD;
      neuromuscular blocking agents.&#xD;
&#xD;
      The study will have two periods:&#xD;
&#xD;
        -  Period 1 - Evaluation at PACU arrival.&#xD;
&#xD;
        -  Period 2 - Collection of hospital patient discharge data.&#xD;
&#xD;
      A total of 360 patients will be included from approximately 10 centers in Portugal, where the&#xD;
      PACU is adjacent to the Operating Room (OR). Each center should recruit between 30 and 40&#xD;
      patients.&#xD;
&#xD;
      Each subject is considered to be enrolled in the study when the subject has provided written&#xD;
      informed consent.&#xD;
&#xD;
      Enrollment will be stopped when approximately 360 patients are recruited.&#xD;
&#xD;
      A subject is considered to have completed the trial after all of the protocol specified&#xD;
      activities are completed. A subject is considered to have discontinued after he/she has&#xD;
      withdrawn consent or has been discontinued.&#xD;
&#xD;
      Overall, study start is when the first site is initiated and study ends at database lock.&#xD;
&#xD;
      During the routine preoperative anesthesia visit the patient will be asked to participate in&#xD;
      the study. A description of the study will be provided to the patient by the investigator or&#xD;
      qualified designee and any questions will be properly answered. If the patient agrees to&#xD;
      participate in the study an informed consent form (ICF) will be signed.&#xD;
&#xD;
      Consent must be documented by the subject's dated signature or by the subject's legally&#xD;
      acceptable representative's dated signature on a consent form along with the dated signature&#xD;
      of the person conducting the consent discussion. A copy of the signed and dated consent form&#xD;
      should be given to the subject before participation in the study.&#xD;
&#xD;
      The initial informed consent form, any subsequent revised written informed consent form and&#xD;
      any written information provided to the subject must receive the IRB/ERC's (Institutional&#xD;
      Review Board) ) approval/favorable opinion in advance of use. The subject or his/her legally&#xD;
      acceptable representative should be informed in a timely manner if new information becomes&#xD;
      available that may be relevant to the subject's willingness to continue participation in the&#xD;
      study.&#xD;
&#xD;
      All consented subjects will be given a unique patient number that will be used to identify&#xD;
      the subject for all procedures. Each subject will be assigned only one patient number.&#xD;
&#xD;
      Immediately after patient arrival in the PACU and as soon as clinically adequate (basic&#xD;
      monitoring and oxygen therapy in place) the anesthesiologist assigned to the PACU (who was&#xD;
      not involved in the anesthetic procedure) will collect demographic data (gender, age, weight,&#xD;
      height), vital signs (heart rate, blood pressure, oxygen saturation and temperature).&#xD;
      Neuromuscular blockade (TOF Ratio) will be measured. Clinical history, co-morbidities,&#xD;
      surgical diagnosis, ASA (American Society of Anesthesiology) classification and perioperative&#xD;
      medication data (dosage and last administration time) will be collected as well.&#xD;
&#xD;
      As this is an observational study, intra-operative monitoring of neuromuscular blockade will&#xD;
      not be mandatory by protocol and will be left at the discretion of the anesthesiologist as&#xD;
      according to the clinical practice. Only information about whether this evaluation was&#xD;
      performed or not, and if yes if it was used quantitative or qualitative methods, will be&#xD;
      collected in the CRF (case report form) .&#xD;
&#xD;
      Neuromuscular blockade evaluation Neuromuscular blockade will be evaluated using a&#xD;
      quantitative method. Three consecutive TOF stimulations will be applied. In case these 3&#xD;
      measures differ more than 20%, another sequence of 3 consecutive TOF measurements will be&#xD;
      considered. If after the 2nd sequence the 3 consecutive TOF measurements still differ more&#xD;
      than 20% between the maximum and the minimum the patient will be excluded.&#xD;
&#xD;
      This study will reflect real life clinical practice. The anesthetic technique in terms of&#xD;
      drugs and type of monitoring used will be of entire responsibility of the anesthesiologist.&#xD;
&#xD;
      All study activities will be consistent with EU (European Union) directive 2001/20/EC section&#xD;
      for non- interventional studies :&#xD;
&#xD;
        -  NMBAs (neuromuscular blocking agents) and reversal agents (as well as all drugs which&#xD;
           will be used during the anesthesia) administration will be done in accordance with&#xD;
           routine anesthesiology practice and labeling of these medicine products;&#xD;
&#xD;
        -  No further interventional means, methods or procedures, are scheduled for subjects,&#xD;
           which would otherwise not be applied;&#xD;
&#xD;
        -  Furthermore, there will be no additional visits to the hospital or a mandatory visit&#xD;
           schedule, deviating from daily clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Postoperative Residual Neuromuscular Blockade</measure>
    <time_frame>No more than 10 minutes after operating room exit</time_frame>
    <description>Percentage of patients arriving PACU with a TOF ratio &lt; 0.9 measured as average of 3 consecutive TOF stimulations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade</measure>
    <time_frame>no more than 10 minutes after operating room exit</time_frame>
    <description>Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio &lt; 0.7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Postoperative Residual Blockade and the Use of Reversal Agents</measure>
    <time_frame>no more than 10 minutes after operating room exit</time_frame>
    <description>Association of postoperative residual blockade and the use of reversal agents (neostigmine, sugammadex or none)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Postoperative Residual Blockade and the Use of Intra-operative Monitoring of Neuromuscular Blockade</measure>
    <time_frame>no more than 10 minutes after operating room exit</time_frame>
    <description>To evaluate the association of postoperative residual blockade and the use of intra-operative monitoring of neuromuscular blockade</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Association of Postoperative Residual Blockade and ASA Status</measure>
    <time_frame>no more than 10 minutes after operating room exit</time_frame>
    <description>To evaluate the association of postoperative residual blockade with co- morbidities and ASA status</description>
  </other_outcome>
  <enrollment type="Actual">366</enrollment>
  <condition>Residual Neuromuscular Blockade</condition>
  <condition>Residual Paralysis, Post-Anesthesia</condition>
  <condition>Observational Study</condition>
  <condition>Complication of Anesthesia</condition>
  <condition>Neuromuscular Blockade</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for surgery on 10 centers that accepted to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older;&#xD;
&#xD;
          -  Informed consent signed;&#xD;
&#xD;
          -  Admission for elective surgery;&#xD;
&#xD;
          -  Administration of non-depolarizing NMBAs during surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Admission for emergency surgery;&#xD;
&#xD;
          -  Reoperation on the same hospital admission;&#xD;
&#xD;
          -  More than 10 minutes elapsed between extubation and neuromuscular block monitoring at&#xD;
             PACU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simao Esteves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar do Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Prof. Fernando Fonseca, EPE</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Baixo Vouga</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Tamega Sousa</name>
      <address>
        <city>Penafiel</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar S. João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Vila Nova Gaia/Espinho</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Tondela Viseu</name>
      <address>
        <city>Viseu</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2021</results_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar do Porto</investigator_affiliation>
    <investigator_full_name>Simao Esteves</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03417804/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients &gt; 18 years old submitted to surgery under general anesthesia with the use of non-depolarizing neuromuscular blocking agents from 10 public Portuguese hospitals</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients Proposed for Elective Surgical Procedures</title>
          <description>A multicentre prospective observational study in adult patients undergoing different types of elective surgical procedures requiring general anaesthesia with non-depolarizing NMBAs was conducted between July 2018 and July 2019 at 10 public Portuguese hospitals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="366">at least 360 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Proposed for Elective Surgical Procedures</title>
          <description>A multicentre prospective observational study in adult patients undergoing different types of elective surgical procedures requiring general anaesthesia with non-depolarizing NMBAs was conducted between July 2018 and July 2019 at 10 public Portuguese hospitals</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="48" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Postoperative Residual Neuromuscular Blockade</title>
        <description>Percentage of patients arriving PACU with a TOF ratio &lt; 0.9 measured as average of 3 consecutive TOF stimulations</description>
        <time_frame>No more than 10 minutes after operating room exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Proposed for Elective Surgical Procedures</title>
            <description>A multicentre prospective observational study in adult patients undergoing different types of elective surgical procedures requiring general anaesthesia with non-depolarizing NMBAs was conducted between July 2018 and July 2019 at 10 public Portuguese hospitals&#xD;
20 patients out of 366 presented with TOFr&lt; 0.9 which represents an incidence of 5,5%</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Postoperative Residual Neuromuscular Blockade</title>
          <description>Percentage of patients arriving PACU with a TOF ratio &lt; 0.9 measured as average of 3 consecutive TOF stimulations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade</title>
        <description>Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio &lt; 0.7</description>
        <time_frame>no more than 10 minutes after operating room exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Proposed for Elective Surgical Procedures</title>
            <description>A multicentre prospective observational study in adult patients undergoing different types of elective surgical procedures requiring general anaesthesia with non-depolarizing NMBAs was conducted between July 2018 and July 2019 at 10 public Portuguese hospitals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade</title>
          <description>Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio &lt; 0.7</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Postoperative Residual Blockade and the Use of Reversal Agents</title>
        <description>Association of postoperative residual blockade and the use of reversal agents (neostigmine, sugammadex or none)</description>
        <time_frame>no more than 10 minutes after operating room exit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Postoperative Residual Blockade and the Use of Intra-operative Monitoring of Neuromuscular Blockade</title>
        <description>To evaluate the association of postoperative residual blockade and the use of intra-operative monitoring of neuromuscular blockade</description>
        <time_frame>no more than 10 minutes after operating room exit</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association of Postoperative Residual Blockade and ASA Status</title>
        <description>To evaluate the association of postoperative residual blockade with co- morbidities and ASA status</description>
        <time_frame>no more than 10 minutes after operating room exit</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <desc>Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients Proposed for Elective Surgical Procedures</title>
          <description>A multicentre prospective observational study in adult patients undergoing different types of elective surgical procedures requiring general anaesthesia with non-depolarizing NMBAs was conducted between July 2018 and July 2019 at 10 public Portuguese hospitals</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="366"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Severe residual neuromuscular blockade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmunary thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="366"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to its observational nature, it was not possible to standardize practices between centres.&#xD;
A convenience sample was used (patients were included when investigators were scheduled to PACU), what may have biased the study sample</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Simão Esteves</name_or_title>
      <organization>Centro Hospitalar do Porto</organization>
      <phone>+351222077549</phone>
      <email>simao.esteves@me.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

